Effect Of Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers On the Clinical Outcome In COVID-19 Patients With Hypertension
No Thumbnail Available
Date
2021-12-31
0000-0002-5632-9425 Journal Title
Journal ISSN
Volume Title
Publisher
Brieflands
Abstract
Background: Hypertension is the main factor to predict the severity and mortality of COVID-19. The use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) is challenging. This study aimed to investigate the effect of ACEIs and ARBs on clinical outcomes in COVID-19 patients with hypertension. Materials and Methods: This cross-sectional study was carried out on 498 patients who were referred to Razi hospital following COVID-19 development and also had hypertension. Patients were divided into two groups receiving drugs in the ACEIs and ARB's groups and those not receiving these drugs. The primary outcome was death up to one month after the onset of symptoms. Results: Cardiovascular disease in patients taking ACEIs/ARBs was higher (p0.05). Seventy-nine patients (15.86%) were admitted to ICU in which 62.03% of these patients died while the non-ICU mortality rate was 14.8% (Odds Ratio = 9.40; 95% CI: 5.54 to 15.95, p